$TLPH News
Last published 19h ago
- 19h agoTLPHTALPHERA, INC. - EXHIBIT 99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 19h agoTLPHTalphera Reports Third Quarter 2026 Financial Results and Provides Business UpdatePR NewswireBriefing document submitted to FDA for a Sprint Meeting requesting a close of the NEPHRO CRRT study enrollment based on number of patients enrolled as of...
- 2mo agoTLPHTalphera to Participate in the H.C. Wainwright 28th Annual Global Investment ConferencePR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
- 3mo agoTLPHTalphera Announces Second Quarter 2026 Financial Results and Provides Corporate UpdatePR NewswireNEPHRO CRRT clinical study of nafamostat is 75% enrolled; expected to be complete this yearDraft 2026 KDIGO guidelines added nafamostat as an acceptable CRRT anticoagulant, a positive change from previous
- 3mo agoTLPHTalphera to Report Second Quarter 2026 Financial Results on Wednesday, August 12, 2026PR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
- 6mo agoTLPHTalphera Announces First Quarter 2026 Financial Results and Provides Corporate UpdatePR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
- 6mo agoTLPHTalphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 13, 2026PR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
- 7mo agoTLPHTalphera Announces Two Abstracts Accepted for Presentation at AKI & CRRT 2026PR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
- 7mo agoTLPHTalphera Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdatePR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
- 7mo agoTLPHTalphera to Host Virtual Investor & Analyst Event to Discuss Niyad® for Use in Continuous Renal Replacement Therapy (CRRT), on March 23, 2026PR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
- 8mo agoTLPHTalphera Announces 50% Enrollment Milestone in Ongoing NEPHRO-CRRT Registrational TrialPR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
- 1y agoTLPHCRMDTalphera Announces Third Quarter 2025 Financial Results and Provides Corporate UpdatePR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
- 1y agoTLPHTalphera to Host Third Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, November 12, 2025PR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
- 1y agoTLPHCRMDTalphera Announces the Appointment of Joe Todisco to Board of DirectorsPR NewswireTalphera, Inc. (Nasdaq: TLPH), (Talphera), a specialty pharmaceutical company focused on the development and commercialization of innovative...
- 1y agoCRMDTLPHCorMedix Announces Strategic Minority Investment in TalpheraGlobeNewswireBERKELEY HEIGHTS, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. ("CorMedix") (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening
- 1y agoTLPHCRMDTalphera Announces Private Placement Financing of up to $29 Million Priced At-the MarketPR NewswireTalphera, Inc. (Nasdaq: TLPH), (Talphera), a specialty pharmaceutical company focused on the development and commercialization of innovative...
- 1y agoTLPHTalphera Announces Achievement of 17 Patient Enrollment Milestone in NEPHRO CRRT Pivotal TrialPR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
- 1y agoTLPHTalphera, Inc. (TLPH) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoTLPHTalphera Announces Second Quarter 2025 Financial Results and Provides Corporate UpdatePR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
- 1y agoTLPHTalphera to Host Second Quarter Financial Results and Corporate Update Call and Webcast on Thursday, August 14, 2025PR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
- 1y agoTLPHTalphera Announces First Quarter 2025 Financial Results and Provides Corporate UpdatePR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
- 1y agoTLPHTalphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 14, 2025PR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
- 1y agoTLPHTalphera Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdatePR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
- 1y agoTLPHTalphera Announces Agreement with the FDA to Reduce the NEPHRO CRRT Study Size to 70 Patients From 166 and a Private Placement Financing Priced At-the Market of up to $14.8 MillionPR NewswireTalphera, Inc. (Nasdaq: TLPH), (Talphera), a specialty pharmaceutical company focused on the development and commercialization of innovative...
- 1y agoTLPHTalphera to Host Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update Call and Webcast on Monday, March 31, 2025PR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
- 1y agoTLPHTalphera Announces Agreement with the FDA for Prior Approval Supplement Review to Reduce the Number of Patients in the NEPHRO CRRT StudyPR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
- 1y agoTLPHOLMASYNACTMGTX+1Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive DirectorsPR NewswireAscentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global...
- 1y agoTLPHTalphera, Inc. (TLPH) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoTLPHTalphera Announces Third Quarter 2024 Financial Results and Provides Corporate UpdatePR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
- 2y agoTLPHTalphera to Host Third Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, November 13, 2024PR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
- 2y agoTLPHTalphera to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual SummitPR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
- 2y agoTLPHTalphera to Participate in the H.C. Wainwright 26th Annual Global Investment ConferencePR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
- 2y agoTLPHTalphera Announces First Patient Enrolled in the Registrational Trial Evaluating Nafamostat for Anticoagulation of the Extracorporeal CircuitPR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
- 2y agoTLPHTalphera, Inc. (TLPH) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoTLPHTalphera Announces Second Quarter 2024 Financial Results and Provides Corporate UpdatePR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
- 2y agoTLPHTalphera to Host Second Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, August 14, 2024PR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
- 2y agoTLPHTalphera Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)PR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
- 2y agoTLPHTalphera to Participate at A.G.P. Virtual Healthcare ConferencePR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
- 2y agoTLPHTalphera, Inc. (TLPH) Q1 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoTLPHTalphera Announces First Quarter 2024 Financial Results and Provides Corporate UpdatePR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
- 2y agoTLPHTalphera to Host First Quarter 2024 Financial Results Call and Webcast on Tuesday, May 14, 2024PR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
- 2y agoTLPHTalphera, Inc. (TLPH) Q4 2023 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoTLPHTalphera Announces Fourth Quarter 2023 Financial Results and Provides Corporate UpdatePR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
- 2y agoTLPHTalphera Announces Reduction in Size of its Board of Directors from Ten to Seven MembersPR NewswireTalphera, Inc. (Nasdaq: TLPH), (Talphera), a specialty pharmaceutical company focused on the development and commercialization of innovative...
- 2y agoTLPHTalphera to Host Fourth Quarter and Full-Year 2023 Financial Results Call and Webcast on March 6, 2024PR NewswireTalphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative...
- 2y agoTLPHTalphera Announces $26 Million Capital Commitment Through a Combination of a Non-Dilutive Royalty Monetization and Equity OfferingPR NewswireTalphera, Inc. (Nasdaq: TLPH), (Talphera), a specialty pharmaceutical company focused on the development and commercialization of innovative...